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Précis 39 
Mifepristone ingestion without subsequent misoprostol administration in first-trimester 40 
gestations can result in hemorrhage and poses safety concerns.  41 
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Abstract 42 
Objective: To estimate the efficacy and safety of mifepristone antagonization with high-dose 43 
oral progesterone. 44 
Methods: We planned to enroll 40 women in a double-blind, placebo-controlled, randomized 45 
trial. We enrolled women 44-63 days gestation with ultrasound-confirmed gestational cardiac 46 
activity planning surgical abortion. Participants ingested mifepristone 200 mg and initiated oral 47 
progesterone 400 mg or placebo 24 hours later twice daily for 3 days, then once daily until their 48 
planned surgical abortion 14-16 days after enrollment. Follow-up visits were scheduled 3±1, 7±1 49 
and 15±1 days after mifepristone intake with ultrasonography and blood testing for human 50 
chorionic gonadotropin and progesterone. Participants exited from the study when they had their 51 
surgical abortion or earlier for gestational cardiac activity absence, gestational sac expulsion or 52 
medically indicated suction aspiration. We assessed the primary outcome of continued 53 
gestational cardiac activity at approximately two weeks (15±1 days), side effects after drug 54 
ingestion, and safety outcomes including hemorrhage and emergent treatment.  55 
Results: We enrolled participants from February to July 2019 and stopped enrollment after 12 56 
patients for safety concerns. Mean gestational age was 52.5 days. Two (one per group) 57 
voluntarily discontinued 3 days after mifepristone ingestion for subjective complaints (nausea 58 
and vomiting, bleeding). Among the remaining 10 women (5 per group), gestational cardiac 59 
activity continued for two weeks in 4  in the progesterone group and 2  in the placebo group. One 60 
woman in the placebo group had no gestational cardiac activity 3 days after mifepristone use. 61 
Severe hemorrhage requiring ambulance transport to hospital occurred in 3 patients; 1 received 62 
progesterone (complete expulsion, no aspiration) and 2 received placebo (aspiration for both, one 63 
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required transfusion). We halted enrollment after the third hemorrhage. No other significant side 64 
effects were reported.  65 
Conclusion: We could not estimate the efficacy of progesterone for mifepristone antagonization 66 
due to safety concerns when mifepristone is administered without subsequent prostaglandin 67 
analogue treatment. Women in early pregnancy who use only mifepristone may be at high risk of 68 
significant hemorrhage. 69 
Clinical Trial Registration: ClinicalTrials.gov, NCT03774745. 70 
  71 
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Introduction 72 
In the United States, approximately 862,000 abortions occur per year of which almost 73 
40% occur using medical abortion (1). The treatment approved by the Food and Drug 74 
Administration (FDA) for medical abortion is a combination of mifepristone and misoprostol 75 
through 70 days gestation (2). Mifepristone acts as a competitive progesterone receptor 76 
antagonist and promotes decidual necrosis to weaken implantation, enhances uterine sensitivity 77 
to prostaglandins, and softens the cervix (3). Accordingly, mifepristone has some activity to 78 
induce abortion when used alone. However, overall efficacy is generally 80% or less and these 79 
studies typically included women less than 49 days gestation (4). Medical abortion efficacy is 80 
improved significantly with the addition of a prostaglandin analogue (4). Mifepristone followed 81 
in 24-48 hours by misoprostol is 96-97% effective through 70 days gestation; however, as 82 
gestation advances from 49 to 70 days, complete abortion rate decreases and continuing 83 
pregnancy rate increases (2). Approximately 0.3% of women at 49 days or less experience a 84 
continuing pregnancy compared to 3.1% of women at 64 to 70 days (2). A recent United 85 
Kingdom study of women who initiated medical abortion at 64 to 70 days found that 9/89 (10%) 86 
women with continuing pregnancies detected at follow-up opted to continue the pregnancy (5). 87 
Case series have reported that some women may change their minds about terminating 88 
their pregnancies after ingesting mifepristone and prior to misoprostol treatment (6-8). Although 89 
an exact proportion is unknown, the best estimate is that <0.005% of women who use 90 
mifepristone choose to continue their pregnancies (9). Because mifepristone binds strongly to the 91 
progesterone receptor and has a long half-life (4), some scientists believe that this action is 92 
potentially irreversible. However, others have questioned this theory and believe that providing 93 
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high doses of progesterone may antagonize the effects of mifepristone when administered for 94 
abortion (6).  95 
No clinical trials have been performed to adequately study antagonizing mifepristone 96 
with progesterone treatment. Case series reported to date have significant limitations, including 97 
using investigational treatment (high-dose progesterone) following mifepristone ingestion 98 
without consenting women for this experiment, incomplete reporting of outcomes, use of varying 99 
progesterone doses, routes and durations, and lack of control groups to understand true efficacy 100 
(6-8). The largest case series (547 women evaluated) reported a 48% continuing pregnancy rate 101 
using various progesterone regimens, with the highest rates (64-68%) using various 102 
intramuscular or oral treatments (8). To address these issues, we conducted a double-blind 103 
placebo-controlled randomized trial to evaluate continuing pregnancy rates, safety, and side 104 
effects of high-dose oral progesterone in women who used mifepristone during early pregnancy. 105 
 106 
 107 
Methods 108 
We conducted this randomized, double-blind, placebo-controlled trial at the University of 109 
California, Davis Medical Center. We approached women who had completed counseling and 110 
consent for a surgical abortion and were 63 days gestation or less about study participation. 111 
Inclusion criteria were 18 years or older, English-speaking, singleton pregnancy, and willingness 112 
to delay the abortion by approximately two weeks. Exclusion criteria were medical 113 
contraindications to medical abortion per the mifepristone FDA label (2), an allergy to 114 
mifepristone or progesterone, or a peanut allergy (on-label contraindication to oral progesterone). 115 
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The UC Davis Institutional Review Board approved this study and all participants gave written 116 
study consent prior to beginning any study procedures.  117 
The screening visit included obtaining study consent, recording demographic 118 
information, soliciting baseline pregnancy symptoms (subjectively rated as none, mild, moderate 119 
or severe), and inquiring if they had used mifepristone or progesterone previously. Patients for 120 
whom transvaginal ultrasonography demonstrated gestational cardiac activity and a gestational 121 
age 44-63 days gestation based on Goldstein and Wolfson’s criteria (10) could enroll that day. 122 
Women less than 44 days gestation at screening returned for enrollment, at which time 123 
transvaginal ultrasonography was repeated to confirm gestational cardiac activity and gestational 124 
age.  125 
Enrolled participants had blood drawn for human chorionic gonadotropin (hCG) and 126 
progesterone levels, then swallowed mifepristone 200 mg in front of an investigator. Study 127 
treatment (progesterone or placebo) was prepared by the UC Davis Investigational Drug Service 128 
(IDS) by placing 38 capsules of progesterone 200 mg or similar-appearing placebo capsules in 129 
opaque pill containers. The IDS could not over-encapsulate the drugs due to product size. The 130 
IDS performed the randomization allocation using a computer-generated random sequence in 131 
blocks of four, sequentially numbered the containers, and maintained the randomization log to 132 
ensure drug allocation concealment until study completion. Participants were instructed to start 133 
study treatment 24 hours after mifepristone ingestion by taking two capsules twice daily for three 134 
days then two capsules once daily until the study exit visit. We chose this dosing regimen 135 
because it was the most effective option previously described in a case series of mifepristone 136 
antagonization (8). Participants received a diary to document any side effects and capsule intake. 137 
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Participants also received the standard medical abortion bleeding and side effect instructions 138 
distributed to medical abortion patients at the University of California, Davis.  139 
Research staff contacted participants 24 hours after mifepristone administration to 140 
confirm the start of study treatment. Follow-up visits were scheduled 3±1, 7±1 and 15±1 days 141 
after mifepristone intake. Each visit included diary review, assessment of symptoms/drug side 142 
effects, ultrasonography to establish presence or absence of gestational cardiac activity, and 143 
blood testing for hCG and progesterone. Additionally, a research coordinator independently 144 
counted unused study drug to maintain investigator blinding. The subject’s planned surgical 145 
abortion was scheduled concurrent with her last study visit. Participants exited from the study 146 
when they had their surgical abortion, or earlier for gestational cardiac activity absence, 147 
gestational sac expulsion, or medically-indicated suction aspiration. At the final visit, 148 
participants were asked if they knew what treatment they received or looked up the capsules 149 
online for identification. 150 
The primary outcome was continuing pregnancy with presence of gestational cardiac 151 
activity after approximately two weeks (15±1 days). Secondary outcomes included expulsion 152 
rates over two weeks, change in hCG and progesterone during treatment, study drug side effects, 153 
and safety outcomes (e.g., hemorrhage, emergency department visit, emergent suction 154 
aspiration). Safety evaluations (adverse events review) were performed by the principal 155 
investigator after each subject completed the study and at research review meetings every two 156 
weeks by the primary study team. The principal investigator was responsible for continued safety 157 
oversight and decisions to stop the study for safety reasons. 158 
We estimated a 68% continuing pregnancy rate with oral progesterone treatment based on 159 
a report using the same dosing after mifepristone administration in early pregnancy, stating that 160 
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68% of women had a pregnancy that continued to 20 weeks or more (8). We also estimated that 161 
only 25% of women receiving placebo would have a continuing pregnancy (10). Using 80% 162 
power and α=0.05, 20 participants per group were required.  163 
We performed an intention-to-treat analysis, using Fisher’s Exact Test or Chi-square test 164 
as indicated, t-test for continuous variables and Mann Whitney U for comparing median values.  165 
 166 
Results 167 
We enrolled 12 women from February to July 2019 (Figure 1).  Patient characteristics are 168 
presented in Table 1. Two women exited the study voluntarily related to side effects; both had a 169 
suction aspiration 3 days after mifepristone administration.  The first, in the placebo group, was 170 
48 days at enrollment and had a prior medical abortion. She had increased anxiety about bleeding 171 
that started 2 days after mifepristone use and requested a suction aspiration. The second, in the 172 
progesterone group, had three prior pregnancies and mild nausea and vomiting at baseline. She 173 
had developed increasing nausea and vomiting after enrolling, resulting in dehydration that 174 
required intravenous fluids as an outpatient. She only took two of her four treatment doses before 175 
requesting a suction aspiration. 176 
Overall, 4/6 women in the progesterone group and 2/6 women in the placebo group had a 177 
continuing pregnancy at two weeks.  Excluding the two women who did not finish treatment, 178 
these rates are 4/5 and 2/5 respectively. A detailed listing of individual subject characteristics 179 
and outcomes is included in Appendix 1, available online at http://links.lww.com/xxx. 180 
Four pregnancies did not continue, including one subject at 48 days in the placebo group 181 
who had no gestational cardiac activity 3 days after mifepristone use and had an uneventful 182 
suction aspiration. Three other women had severe bleeding requiring ambulance transport to an 183 
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emergency department. The first subject received progesterone treatment after enrollment at 56 184 
days gestation. She reported no bleeding at the first follow-up visit 2 days post mifepristone. 185 
Shortly after her visit, she started having brisk bleeding and called an ambulance. Transvaginal 186 
ultrasound in the emergency department found no gestational sac and a heterogenous 187 
endometrial lining of approximately 1.5 cm. Heavy bleeding lasted about 3 hours overall and no 188 
intervention was needed. The second subject received placebo and enrolled at 60 days gestation. 189 
She noted new mild bleeding at a follow-up visit two days after mifepristone use.  The following 190 
day, she called an ambulance due to onset of heavy vaginal bleeding. In the emergency 191 
department, a study physician found significant heterogenous material in the uterine cavity on 192 
ultrasound exam with continued brisk bleeding, so a suction aspiration was performed. Pathology 193 
demonstrated normal chorionic villi. The third subject also received placebo and enrolled at 60 194 
days gestation. She noted new mild spotting at a follow-up visit two days after mifepristone use.  195 
The following days, she called an ambulance after experiencing hemorrhage. In the emergency 196 
department, a study physician evaluated the subject who had significant brisk bleeding, 197 
hypotension and tachycardia. Transvaginal sonography showed the gestational sac still in the 198 
uterine cavity, so an emergent suction aspiration was performed. This subject’s hemoglobin 199 
decreased in the emergency department from 9.2 to 7.5 gm/dL and she received a one-unit 200 
transfusion of packed red blood cells. At safety contacts two and four weeks later, the subject 201 
reported no issues. We stopped enrollment for safety reasons after the third subject required 202 
emergent evaluation and a transfusion. 203 
Baseline and follow-up serum hCG and progesterone levels are presented in Figures 2 204 
and 3, respectively. Median baseline hCG and progesterone levels for the progesterone group 205 
were 76,776 mIU/mL (range 21,062-126,647 mIU/mL) and 12.4 ng/mL (range 10.5-24.0 206 
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ng/mL), respectively.  Median baseline hCG and progesterone levels for the placebo group were 207 
153,908 mIU/mL; range 25,450-246,638 mIU/mL) and 16.3 ng/mL (range 11.2-18.9 ng/mL), 208 
respectively. In the progesterone group, progesterone levels increased 240-1010% within a few 209 
days of starting treatment among women with continuing gestational cardiac activity at two 210 
weeks whereas the one subject with hemorrhage demonstrated an increase of only 45% despite 211 
being adherent with study drug instructions.  212 
Table 2 describes side effects related to pregnancy or treatment. One subject in the 213 
progesterone group noted the onset of severe nausea and vomiting shortly after mifepristone 214 
intake that preceded progesterone treatment; otherwise, no appreciable differences in 215 
development of new severe side effects were identified between treatment groups. All women 216 
experienced some spotting (n=8) or bleeding (n=9) during treatment except for the subject with 217 
the highest baseline progesterone (24.1 ng/mL). 218 
Only two participants believed they received progesterone, of whom one did (continuing 219 
pregnancy at two weeks) and one did not (hemorrhage requiring emergent aspiration).  The 220 
remaining ten women were evenly split between placebo and unsure. None of the women looked 221 
on the internet to identify the study capsules they received. 222 
 223 
Discussion 224 
Although the study sample size was powered to demonstrate a difference in continuing 225 
pregnancy rates between progesterone and placebo treatment after mifepristone ingestion, we 226 
could not evaluate this outcome due to stopping enrollment for safety reasons. However, we can 227 
make a few global and important conclusions from this very small, randomized trial.  First, 228 
women who receive high-dose oral progesterone treatment do not experience side effects that are 229 
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noticeably different than placebo. Although women using progesterone did report worsening of 230 
some pregnancy symptoms, like vomiting and tiredness, these issues were rarely severe. 231 
Second, and most importantly, are the lessons about treatment safety. Providing treatment 232 
in any medical situation requires a full understanding of the potential benefits and risks. Previous 233 
case series reports do not describe outcomes for the one-third or more women without continuing 234 
pregnancies after progesterone treatment (8). Three of 12 women enrolled experienced very 235 
heavy bleeding resulting in ambulance transport to an emergency department visit, a rate higher 236 
than reported with medical abortion in which 0.6% of women may have emergency department 237 
visits (12). Women who use mifepristone for a medical abortion should be advised that not using 238 
misoprostol could result in severe hemorrhage, even with progesterone treatment. We stopped 239 
the study because of these complications and, thus, could not quantify the full extent of this risk. 240 
Because of the potential dangers for women who opt not to use misoprostol after mifepristone 241 
ingestion, any mifepristone antagonization treatment must be considered experimental.  242 
The study has multiple limitations, primarily the inability to safely reach the enrollment 243 
goal to fully assess the primary outcome. Additionally, blinding for progesterone capsules is 244 
difficult and imperfect; however, we believe we maintained blinding because the women 245 
enrolled had never used progesterone and none looked up the treatment to identify the drug. Of 246 
note, the variability in progesterone level among women in the progesterone group may be 247 
explained by differential oral absorption of progesterone (13). Although one may postulate 248 
another route of progesterone administration might affect the outcome, the case reports in the 249 
literature suggest similar continuing pregnancy rates after oral and intramuscular treatment (8).  250 
Our study established outcomes at two weeks as a surrogate for ongoing pregnancy; as 251 
such, it does not capture those who may still experience pregnancy loss more than 2 weeks after 252 
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mifepristone exposure (14). Accordingly, the outcomes described may not reflect the ultimate 253 
rate of pregnancies that continue past 20 weeks gestation. Progesterone levels declined to levels 254 
near baseline from these high peaks with continued treatment for two weeks. These findings 255 
raise two opposing questions: first, if progesterone can prevent medical abortion following 256 
mifepristone, is treatment necessary for more than two weeks?  The case report from which the 257 
oral progesterone regimen for this study was based used the treatment through the “end of the 258 
first trimester” (8). Second, do those treated with placebo just expel the pregnancy earlier than 259 
those that receive progesterone but no overall long-term difference in continuing pregnancy 260 
exists? 261 
The context of this study is the question of whether a woman who has taken mifepristone 262 
200 mg for a medical abortion and decides not to proceed with misoprostol treatment will be less 263 
likely to expel the pregnancy if she receives high-dose progesterone as compared to no 264 
treatment. Although mifepristone can cause abortion when used by itself in early pregnancy, the 265 
exact rate is not clear because studies were small and limited primarily to pregnancies of 49 days 266 
or less. Medical abortion today is used through 70 days gestation. Additionally, a background 267 
rate of pregnancy loss is present regardless of mifepristone treatment.  In women with gestational 268 
cardiac activity demonstrated by ultrasonography at 6-10 weeks, 13.4% will spontaneously have 269 
an early pregnancy loss (15). 270 
This study, although small, provides important insight into the safety of mifepristone 271 
antagonization with progesterone during early pregnancy.  We should not dismiss mifepristone 272 
antagonization as impossible; fully understanding outcomes will serve as the best means to 273 
accurately inform our patients, the medical community, and legislators. Existing literature before 274 
this study is comprised of case reports and series which are not evidence of efficacy and do not 275 
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address safety (6-8). This level of evidence is inadequate to support or refute the benefits and 276 
risks of any treatment. Unfortunately, legislators often fail to understand differences in level of 277 
evidence and some states now require physicians who provide medical abortion to counsel 278 
women that the actions of mifepristone can be reversed if they change their mind. In 2015, 279 
Arkansas implemented mandatory abortion reversal counseling followed by Arizona (later 280 
repealed in 2016), South Dakota, Utah, Idaho and, most recently, North Dakota. Several other 281 
states have introduced and passed legislation, although some were vetoed by the Governor. 282 
Abortion is no different than any other medical treatment when considering clinical practice 283 
guidelines; laws should not mandate counseling or provision of any treatment when we don’t 284 
fully understand treatment efficacy (including best route of administration, dose and duration) 285 
and safety. 286 
The dilemma that has been created around mifepristone antagonization only exists 287 
because of the void in high-quality research addressing the issue. For now, such a treatment is 288 
experimental and should only be offered in Institutional Review Board approved human clinical 289 
trials to ensure proper oversight.  290 
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Legend 329 
Figure 1. 330 
Title: 331 
Participant flow in women who received mifepristone 200 mg followed by progesterone for up to 332 
two weeks 333 
Footer: 334 
GCA: gestational cardiac activity 335 
Figure 2. 336 
Title: 337 
Serum hCG levels in women who received mifepristone 200 mg followed by progesterone for up 338 
to two weeks  339 
Footer: 340 
hCG: human chorionic gonadotropin 341 
* Participants experiencing hemorrhage 342 
† Participant experienced loss of gestational cardiac activity 343 
‡ Value >270,000 (upper limit of hCG test) 344 
¥ Discontinued related to side effects 345 
Figure 3. 346 
Title: 347 
Progesterone levels in women who received mifepristone 200 mg followed by progesterone 348 
(Figure A) or placebo (Figure B) for up to two weeks 349 
Header Figure 2A:  Progesterone users 350 
Header Figure 2B:  Placebo users 351 
Footer: 352 
* Participants experiencing hemorrhage 353 
† Participant experienced loss of gestational cardiac activity 354 
‡ Discontinued related to side effects. 355 
  356 
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Table 1. Characteristics at enrollment for women receiving mifepristone and randomized to 358 
progesterone or placebo treatment 359 
Characteristic 
 
Total 
N=12 
 
Progesterone 
n=6 
Placebo 
n=6 
 
Age (years) 27.3 (20.9-39.6) 29.8 (24.6-39.6) 24.1 (20.9-33.8) 
    
Gestational age (days) 52.5 (47-61) 49.5 (47-56) 55 (48-61) 
    
Body Mass Index (kg/m2) 24.6 (19.0-52.3) 24.8 (19.0-36.4) 24.6 (22.7-52.3) 
 Obese (≥30.0) 4 (33%) 2 (33%) 2 (33%) 
    
Race    
 White 3 (25%) 0 3 (50%) 
 Black or African American 5 (42%) 4 (67%) 1 (17%) 
 Asian 4 (33%) 2 (33%) 2 (33%) 
    
Ethnicity 
 Hispanic or Latina 
 
2 (17%) 
 
1 (17%) 
 
1 (17%) 
    
Marital Status    
 Never married 7 (58%) 3 (50%) 4 (67%) 
 Married 2 (17%) 1 (17%) 1 (17%) 
 Divorced/Separated 3 (25%) 2 (33%) 1 (17%) 
    
Education Level    
High School Graduate 2 (17%) 0 2 (33%) 
Some college 9 (75%) 5 (83%) 4 (67%) 
College Graduate 1 (8%) 1 (17%) 0 
    
Gravidity 4 (1-12) 4.5 (1-10) 3.5 (1-12) 
 >3 prior pregnancies 7 (58%) 4 (67%) 3 (33%) 
    
Parity 1 (0-6) 1.5 (0-6) 0.5 (0-3) 
 Nulliparous 4 (33%) 1 (17%) 3 (33%) 
    
  360 
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Prior Abortion 9 (75%) 4 (67%) 5 (83%) 
 >3 prior abortions 4 (33%) 2 (33%) 2 (33%) 
    
Past Mifepristone Use 4 (733%) 1 (17%) 3 (33%) 
    
Prior Progesterone Use 0 0 0 
    
Data are presented as n (%) or median (range) 361 
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Table 2. Side effects* noted during follow-up of women in early pregnancy receiving mifepristone and randomized to progesterone or 362 
placebo treatment for up to two weeks 363 
 364 
 
Reported at Baseline Increased from Baseline† Increased to severe during 
follow-up† 
 
 
Progesterone 
n=6 
Placebo  
n=6 
Progesterone 
n=6 
Placebo  
n=6 
Progesterone 
n=6 
Placebo  
n=6 
Nausea 4 (67%) 5 (83%) 2 (33%) 2 (33%) 2 (33%) 1 (17%) 
Vomiting 2 (33%) 3 (50%) 4 (67%) 0 2 (33%) 0 
Mastalgia 4 (67%) 5 (83%) 1 (17%) 0 0 0 
Tiredness 5 (83%) 4 (67%) 3 (50%) 0 0 1 (17%) 
Mood changes 4 (67%) 5 (83%) 0 0 1 (17%) 0 
Reflux 2 (33%) 2 (33%) 1 (17%) 0 0 0 
Dizziness 2 (33%) 1 (17%) 0 0 0 0 
Bleeding 0 0 4 (67%) 4 (67%) 1 (17%) 3 (50%) 
Spotting 1 (17%) 1 (17%) 3 (50%) 4 (67%) 0 0 
Cramping 3 (50%) 2 (33%) 4 (67%) 5 (83%) 0 0 
 365 
* subjectively assessed by participant as none, mild, moderate or severe 366 
† at any time during follow-up 367 
Data are presented as n (%) 368 
Creinin et al 
 
Appendix.  Individual subject characteristics at enrollment and outcomes for women receiving mifepristone 200 mg and randomized 
to progesterone or placebo treatment 
 
 
 
BMI: body mass index; GCA: gestational cardiac activity; ER: emergency room; L&D: labor and delivery; N/A: not applicable 
* Initiated on study day 2 (24 hours after mifepristone ingestion) 
† Day 1: day of mifepristone administration 
 
Subject 
Number Study group*
Age 
(years)
Gestational 
Age (days) Race Ethnicity Education Marital Status Smoking Alcohol
Marijuana 
Use Drug Use
Total 
Pregnancies
Vaginal  
Delivery
Cesarean 
Delivery Miscarriages Abortions
Weight 
(kg)
BMI 
(kg/m2)
1 Progesterone 24.6 53 Asian Not Hispanic Some college Never married Never Never Never Never 1 0 0 0 0 84.2 32.9
2 Progesterone 30.9 50 Black Not Hispanic Some college Separated Never Current Current Never 8 3 0 0 4 68.9 23.8
3 Placebo 20.9 50 Asian Not Hispanic Some college Never married Never Never Never Never 1 0 0 0 0 61.8 24.1
4 Placebo 22.6 48 White Hispanic Some college Married Current Current Current Current 2 0 0 0 1 152.0 52.3
5 Progesterone 39.6 49 Black Not Hispanic Some college Never married Current Never Never Never 5 2 0 0 2 51.8 19.0
6 Placebo 24.8 61 Asian Not Hispanic Some college Never married Never Current Current Never 3 0 0 1 1 66.7 24.4
7 Placebo 23.5 48 White Not Hispanic High School graduate Never married Former Never Current Never 7 0 1 0 5 71.8 22.7
8 Progesterone 27.7 56 Black Not Hispanic Some college Never married Never Current Never Never 10 1 0 1 7 100.8 36.4
9 Progesterone 31.9 47 Asian Not Hispanic College graduate Married Never Never Never Never 4 0 2 1 0 66.0 25.8
10 Placebo 27.0 60 Black Not Hispanic High School graduate Never married Never Current Current Never 4 2 0 0 1 63.5 24.8
11 Placebo 33.8 60 White Not Hispanic Some college Separated Current Former Former Former 12 6 0 0 5 105.5 34.3
12 Progesterone 28.6 48 Black Hispanic Some college Divorced Never Current Current Never 3 1 0 0 1 53.8 19.7
Subject 
Number
hCG 
(mIU/mL)
Progesterone 
(ng/mL)
Exit
Study Day† FINAL OUTCOME Hospital visit Reason for Hospital visit
1 95,870 12.1 17 Continuing GCA at exit visit No N/A
2 57,681 11.5 16 Continuing GCA at exit visit No N/A
3 113,431 18.9 16 Continuing GCA at exit visit No N/A
4 25,450 13.7 4 No GCA at follow-up visit No N/A
5 107,780 24.1 16 Continuing GCA at exit visit No N/A
6 246,638 18.9 16 Continuing GCA at exit visit No N/A
7 73,018 11.2 4 D&C requested (bleeding, anxiety) No N/A
8 126,647 12.6 3 Expelled pregnancy, no D&C Yes (ER), Day 3 Hemorrhage, hemoglobin 10.4 gm/dL
9 39,660 10.5 4 D&C requested (nausea, vomiting) Yes (L&D), Day 3 Dehydration, nausea, vomiting
10 230,220 16.3 5 Expelled pregnancy, incomplete, emergent D&C Yes (ER), Day 5 Hemorrhage, hemoglobin 9.6 gm/dL
11 194,384 16.7 6 Expelled pregnancy, incomplete, emergent D&C, transfusion Yes (ER), Day 6 Hemorrhage, hemoglobin change 9.2 to 7.5 gm/dL
12 21,062 13.9 15 Continuing GCA at exit visit No N/A
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Allocated to progesterone
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Allocated to placebo
(n=6)
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symptoms
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3±1 days
after enrollment
Discontinued: no 
gestational cardiac activity
(n=1)
Follow-up 2
(n=2)
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hemorrhage
(n=1)
Follow-up 2
(n=4)
Discontinued (n=3)
  Symptoms: 1
  Hemorrhage: 2
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